To verify the AKT-mediated stabilization of p21 protein in PTEN-deficient CRC cells, we used the PI3K inhibitor LY294002 and the AKT inhibitor MK-2206 and evaluated p21 protein half-life in PTEN-deficient CRC cells. This evidence concerns the gene AKT1 and colorectal carcinoma.